1067657-84-4

Upstream product

• 540523-98-6 3-(4-chloro-2-nitro-phenyl)-2-oxo-propionic acid ethyl ester 
• 89-59-8 4-chloro-2-nitrotoluene 
• 27034-51-1 ethyl 6-chloro-1H-indole-2-carboxylate 
• 1067657-85-5 6-chloro-3-[3-(4-chlorobenzyl)-5-phenyl-3H-imidazol-4-yl]-1H-indole-2-carboxylic acid ethyl ester 

Downstream Products

• 1067657-22-0 6-chloro-3-[3-(4-chloro-benzyl)-5-phenyl-3H-imidazol-4-yl]-2-(4,5-dihydrooxazol-2-yl)-1H-indole 
• 1067653-58-0 6-chloro-3-[3-(4-chlorobenzyl)-5-phenyl-3H-imidazol-4-yl]-1H-indole-2-carboxylic acid (2-morpholin-4-ylethyl)amide 
• 1067655-26-8 {6-chloro-3-[3-(4-chloro-benzyl)-5-phenyl-3H-imidazol-4-yl]-1H-indol-2-ylmethyl}-(2-morpholin-4-yl-ethyl)-amine 

Relevant academic research and scientific papers

Substituted Heterocycles as Therapeutic agents for treating cancer

MDM2 and MDM4 proteins prevent apoptosis of cancer cells by negatively regulating the transcription factor p53. Compounds according to Formula I are selective antagonists of MDM2 and MDM4 proteins, disrupting the p53/MDM2 and p53/MDM4 complex. These compo

3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.